RxDoctor Payments Data

Roman Leibzon, MD

Interventional Cardiology · Burbank, CANPI 1447252218

Payments from drug & device makers

$950in general payments, 2019–2025

Across 13 payments — averaging $73.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$311
  • Medtronic$223
  • Novo Nordisk$118
  • Regeneron Healthcare Solutions, Inc.$112
  • Redhill Biopharma Inc.$98
  • Boston Scientific$41
  • plus $46 from 2 others

What the payments were for

  • Travel & lodging$19220%
  • Food & beverage$71175%
  • Education$141%
  • Other$333%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$950 in reported general payments places this provider in the 15th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$676,555
Medicare patients
1,277
Services billed
6,327

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban425$564,782
Repatha SureclickEvolocumab136$142,968
XareltoRivaroxaban93$125,920
Praluent PenAlirocumab67$49,475
EntrestoSacubitril/Valsartan29$33,126
BrilintaTicagrelor35$25,531
DiovanValsartan23$19,465
VascepaIcosapent Ethyl15$15,510
Rosuvastatin Calcium555$12,921
CrestorRosuvastatin Calcium12$8,901
LipitorAtorvastatin Calcium12$8,888
Metoprolol Succinate413$6,953
Atorvastatin Calcium622$6,820
Nebivolol Hcl84$6,348
Bumetanide11$4,010

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBrilinta, Crestor$14$34,43247 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →